All the top Biotech & Pharma news in one daily newsletter.

Want to understand how these updates are formatted? Check-out the FAQ.

Have any feedback? I’d love to hear you from - connect with me on LinkedIn. 📣

THE GOOD
Approvals & Labels

Arrowhead Pharmaceuticals wins first FDA approval for Redemplo targeting familial chylomicronemia syndrome via RNA interference
RNAi therapy, metabolic, RNA interference, familial chylomicronemia syndrome, triglyceride reduction - Read more

Celltrion's Remsima (infliximab) liquid formulation wins European Commission approval for inflammatory diseases
Antibody, autoimmune, monoclonal antibody, infliximab, TNF-alpha inhibitor, liquid formulation - Read more

FDA approves AbbVie, Genmab's Epkinly (epcoritamab-bysp) CD20xCD3 bispecific for second-line follicular lymphoma treatment
Antibody, cancer, bispecific antibody, follicular lymphoma, CD20xCD3, combination therapy - Read more

Insmed's BRINSUPRI (brensocatib) wins European Commission approval for non-cystic fibrosis bronchiectasis, first EU-approved treatment
Small molecule, respiratory disease, protease inhibitor, non-cystic fibrosis bronchiectasis, neutrophil elastase - Read more

THE GOOD
Business Development & Partnerships

GSK, Fleming Initiative launch £45M ($59.2M) AI-powered antimicrobial resistance research partnership
Research collaboration, infectious disease, AI/ML, drug discovery - Read more

EvE Bio, DrugBank partner to integrate pharmome-mapping data into drug discovery intelligence platform
Research collaboration, drug discovery, small molecule, AI/ML, data analytics - Read more

Apriori Bio, A*STAR partner on next-generation influenza vaccines using AI antigen design, saRNA technology
Research collaboration, infectious disease, vaccine, AI/ML, self-amplifying RNA - Read more

PRESENTED BY SCIENCE 2 SALES
Keep your expensive BD reps closing deals while we fill the pipeline

Your BD reps should be closing deals, not cold calling. They're too expensive and too skilled to spend hours prospecting.

Science 2 Sales handles the entire outbound motion - cold calls, emails, and LinkedIn outreach - delivering qualified meetings that actually convert. We speak your prospects' scientific language, so the conversations start at a higher level.

The result? Your pipeline stays full while your reps focus on revenue.

We offer a 30 day money back guarantee on your first month - if we don't deliver, you don't pay.

Book a free strategy call to see how we can help.

✅ More Good News ✅

THE GOOD
Clinical Trials

Merck & Co.'s Winrevair (sotatercept) meets Ph2 endpoint for heart failure with preserved ejection fraction treatment
Protein therapy, cardiovascular, activin signaling inhibitor, heart failure with preserved ejection fraction, pulmonary hypertension - Read more

Roche's giredestrant (selective estrogen receptor degrader) succeeds in Ph3 trial for early-stage estrogen receptor-positive breast cancer
Small molecule, cancer, selective estrogen receptor degrader, breast cancer, adjuvant therapy - Read more

Tulex Pharmaceuticals and Artisan Therapeutics' ARD-501 shows clinical benefit in 4 of 6 autism spectrum disorder patients in Ph2a trial
Small molecule, neurological, autism spectrum disorder, behavioral symptoms, irritability - Read more

Vanda Pharmaceuticals' tradipitant (neurokinin-1 antagonist) reduces Wegovy-induced vomiting in Ph2 trial, eyes Ph3 start
Small molecule, metabolic, neurokinin-1 receptor antagonist, GLP-1 side effects, nausea and vomiting - Read more

THE GOOD
Fundraises

Cellbyte raises $2.75M seed funding, AI platform accelerating pharmaceutical drug launches
AI/ML platform, data analytics, software platform, market access - Read more

Lifordi raises undisclosed strategic funding from Sanofi for ADC rheumatoid arthritis therapy
Autoimmune, antibody-drug conjugate, rheumatoid arthritis, clinical-stage - Read more

Avanzanite raises €32M ($37.1M) Series A for European rare disease commercialization platform
Rare disease, commercial-stage, specialty pharmaceutical, orphan medicines - Read more

Skeletalis raises $8M funding, bone-targeted osteoporosis therapies for musculoskeletal diseases
Musculoskeletal diseases, small molecule, osteoporosis, bone-targeted technology - Read more

Bambusa Therapeutics raises undisclosed Series A-2, advancing bispecific antibodies for immunology/inflammation
Clinical-stage, bispecific antibodies, immunology, inflammation, antibody platform - Read more

AI Proteins raises $42M Series A, developing miniprotein-based therapeutics platform
Protein design, miniproteins, AI-driven, platform technology, preclinical - Read more [Paywall]

Nuvalent raises $500M public offering, targeted cancer kinase therapies
Cancer, kinase inhibitors, clinical-stage, small molecule - Read more

THE GOOD
Investments

CSL pledges $1.5B investment to expand US plasma manufacturing capabilities over five years
Plasma-derived therapy, rare disease, strategic, major transaction - Read more

Regeneron, increasing US manufacturing investments, invests $2B to convert former magazine factory into drug manufacturing plant, based in New York state
Monoclonal antibody, oncology, infectious disease, major transaction, operational - Read more

THE GOOD
Mergers & Acquisitions

Avadel deems Lundbeck's $2.4B offer superior, giving Alkermes five days to counter existing $2.1B deal (UPDATE - Avadel accepts Alkermes offer)
Small molecule, neurological, strategic, major transaction - Read more

JSR, Adicon acquire Crown Bioscience CRO for $204M with $120M upfront payment
Acquisition, oncology, CRO services, milestone payments - Read more

THE GOOD
Strategic Plans

Zymeworks pivots to royalty-driven model after partner Jazz Pharmaceuticals' late-stage cancer drug success
Monoclonal antibody, oncology, strategic, financial - Read more

PRESENTED BY YOU?
Get the attention of 2300+ Biotech & Pharma Professionals 🤩

Do you offer a biotech/pharma-focused product or service?

Or looking to get investor/analyst interest on your budding start-up?

Considering sponsoring TLDR Biotech to get in-front of an engaged audience of biotech & pharma-focused professionals.

Just reply to this email* or message me on LinkedIn to learn more.

*If you’re reading this on the web version, email [email protected]

THE BAD
Layoffs

Merck & Co. and Bristol Myers Squibb announce over 300 New Jersey layoffs amid cost-cutting restructuring
Operational, cost reduction, strategic, financial - Read more

THE BAD
Regulatory

FDA issues untitled letter to AstraZeneca citing misleading Farxiga TV ad about cardiovascular indications
Small molecule, cardiovascular, regulatory, operational - Read more 

RFK Jr. considered reducing FDA Commissioner Makary's authority amid leadership concerns, staffing turmoil
Regulatory, operational, strategic, leadership - Read more

THE UGLY
No Ugly News Today!

You’re all caught up on the latest Pharma & Biotech News!

TLDR Biotech wants to hear from you! 📣

Have comments/questions/complaints about this newsletter?
Send me an email - I want your brutally honest feedback. 📝

If you find the content useful and think a colleague would too, please share TLDR Biotech with them! ♻️

And lastly - connect with me on LinkedIn!

Disclaimer: Content, news, research, tools, and mention of stock or tradeable securities are for educational and illustrative purposes only and do not imply a recommendation or solicitation to buy or sell a particular security or to engage in any particular investment strategy. Read the full terms & conditions here